GLP-2 research beyond short bowel syndrome

The only approved use of GLP-2 drugs is short bowel syndrome. Researchers have looked further, because the GLP-2 receptor sits in the gut wall, affects blood flow and inflammation, and appears to influence bone. This page sorts that work by how strong it is. "Preclinical" means animals or cells. "Phase 2" means small human trials, usually exploratory.

How GLP-2 works: mostly indirect

The GLP-2 receptor is not on the crypt cells that divide to build new lining. A 2011 review summarised it as located on several other intestinal cell types, with GLP-2 acting through a network of messengers. Small bowel growth has been linked to IGF-1, IGF-2 and ErbB ligands, colon growth to keratinocyte growth factor and IGF-2. The blood flow effect depends on nitric oxide, and the anti-inflammatory effect on a peptide released by enteric nerves in the gut wall. In a 2006 mouse study, mice lacking IGF-1 did not respond to a standard GLP-2 dose with intestinal growth. This mechanism work is almost entirely preclinical.

Gut barrier and inflammation (preclinical)

A leaky gut wall lets bacterial fragments such as lipopolysaccharide into the blood, which can drive low-grade inflammation. In a 2009 study in Gut, obese ob/ob mice fed a prebiotic had lower gut permeability, better tight junctions and less liver and systemic inflammation. The prebiotic raised GLP-2 production, a GLP-2 blocker abolished most of the effect, and a GLP-2 agonist alone reproduced it. This is the main basis for adding GLP-2 activity to obesity drugs, as Zealand did with dapiglutide. It has not been shown in people.

Bone (small human trials)

Bone breakdown normally drops after a meal. GLP-2 appears to be part of that signal. In a 2008 study of 40 people, a single GLP-2 injection reduced the bone resorption marker s-CTX by 24% in controls with an intact gut, but not in people with an ileostomy or jejunostomy, suggesting the effect needs an intact gastrointestinal tract. In a 2009 randomised, placebo-controlled dose-ranging trial in postmenopausal women with low bone density, four months of nightly GLP-2 injections reduced the night-time rise in bone resorption without suppressing bone formation markers, and total hip bone density rose 1.1% from baseline at the 3.2 mg dose. That is a small, short trial with a surrogate endpoint. No fracture data exist, and no GLP-2 drug is being developed for osteoporosis.

Crohn's disease (phase 2 pilot)

Teduglutide was tested in a randomised, placebo-controlled, dose-ranging pilot in 100 people with moderate to severe Crohn's disease, given daily for 8 weeks. At the highest dose, 0.2 mg/kg a day, 44% responded and 32% reached remission, compared with 32% and 20% on placebo. The authors described the differences as numerically higher; 71 of the 100 completed the study. Plasma citrulline rose on teduglutide. Teduglutide was not taken forward as a Crohn's treatment. Many people with short bowel syndrome have Crohn's, so the drug is still used in that group, for their short bowel.

Graft-versus-host disease (phase 2 safety)

After a stem cell transplant, donor immune cells can attack the gut. The STARGAZE trial gave once weekly apraglutide to people with steroid-refractory gut GVHD alongside standard care, with safety as the primary aim. In March 2024 Ironwood reported it was well tolerated through day 91 and that exploratory lower GI responses were maintained. ClinicalTrials.gov lists the trial as terminated by company decision after enrolling 31. There is no evidence yet that GLP-2 drugs treat GVHD.

The tumour question

A peptide that makes gut tissue grow raises an obvious question about tumours. The 2011 review noted studies suggesting GLP-2 may promote carcinogenesis in models of sporadic colon cancer. The teduglutide label cites tumours in rat and mouse studies, warns of "acceleration of neoplastic growth", and requires colonoscopy before starting, after one year and at least every five years. In adult trials, 14 patients developed gut polyps after starting, and three were diagnosed with cancers, two of them lung cancers in heavy smokers. That is too few cases to measure risk, which is why the label relies on surveillance.

What this does not support

None of the research above supports using GLP-2 analogues for gut health, bone, inflammation or weight outside a trial. The approved and late-stage uses are for intestinal failure, under specialist care. GLP-2 is also not the same thing as tirzepatide or retatrutide, despite the online slang.

What to log

If you are in a GLP-2 trial or on treatment, the record that helps most is doses, symptoms, weight and lab results on one timeline. Peptide AI's dose log and bloodwork tracking keep them together, and the GLP-2 hub lists the rest of this section.